悦康药业(688658.SH)：子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准

智通财经2025-12-19

智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局(简称“NMPA”)核准签发的关于YKYY032注射液用于治疗高脂蛋白(a)血症的《药物临床试验批准通知书》。悦康科创于近日获得美国食品药品监督管理局(简称“FDA”)关于同意YKYY032注射液用于治疗高脂蛋白(a)血症进行临床试验的函告(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2592152396?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-19 16:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592152396","market":"us","top_or_hot":-1,"title":"悦康药业(688658.SH)：子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局(简称“NMPA”)核准签发的关于YKYY032注射液用于治疗高脂蛋白(a)血症的《药物临床试验批准通知书》。悦康科创于近日获得美国食品药品监督管理局(简称“FDA”)关于同意YKYY032注射液用于治疗高脂蛋白(a)血症进行临床试验的函告(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1383670.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>悦康药业(688658.SH)：子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n悦康药业(688658.SH)：子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-19 16:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1383670.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局(简称“NMPA”)核准签发的关于YKYY032注射液用于治疗高脂蛋白(a)血症的《药物临床试验批准通知书》。悦康科创于近日获得美国食品药品监督管理局(简称“FDA”)关于同意YKYY032注射液用于治疗高脂蛋白(a)血症进行临床试验的函告(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1383670.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688658","symbol_name":"悦康药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1383670.html","article_id":"2592152396","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592152396","pubTimestamp":1766133582,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，悦康药业 发布公告，公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局核准签发的关于YKYY032注射液用于治疗高脂蛋白血症的《药物临床试验批准通知书》。YKYY032注射液是一款偶联N-乙酰半乳糖胺配体的化学合成双链siRNA药物，通过RNA干扰机制特异性沉默LPA基因转录的mRNA，从源头阻断脂蛋白[Lp]生成，拟用于高脂蛋白血症治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"Yuekang Pharmaceutical (688658. SH): Subsidiary YKYY032 injection was approved by the National Medical Products Administration and FDA for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1.5},"content_text":"智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局(简称“NMPA”)核准签发的关于YKYY032注射液用于治疗高脂蛋白(a)血症的《药物临床试验批准通知书》。悦康科创于近日获得美国食品药品监督管理局(简称“FDA”)关于同意YKYY032注射液用于治疗高脂蛋白(a)血症进行临床试验的函告(StudyMayProceedLetter，IND编号：178774)。YKYY032注射液是一款偶联N-乙酰半乳糖胺(GalNAc)配体的化学合成双链siRNA药物，通过RNA干扰机制特异性沉默LPA基因转录的mRNA，从源头阻断脂蛋白(a)[Lp(a)]生成，拟用于高脂蛋白(a)血症治疗。临床前研究显示，该药物在体外及体内均展现显著药理活性，在多种动物模型中可有效降低LPAmRNA及Lp(a)蛋白水平，在非人灵长类动物中更伴随LDL-C和ApoB水平下降，呈现良好且持久的降血脂效果，且重复给药毒性研究证实其具备良好的安全性与耐受性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592152396","isCrawlerRequest":true}